Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer

Clinical Genitourinary Cancer

Volumn 6, Issue 1, 2008, Pages 46-52

  Bruchovsky, Nicholas ^a,e   Klotz, Laurence ^b   Crook, Juanita ^c   Phillips, Norman ^d   Abersbach, Jonas ^a   Goldenberg, S Larry ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Antiandrogen; Dyspnea; Fatigue; Impotence; Progression free survival

Indexed keywords

CYPROTERONE ACETATE; LEUPRORELIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANGINA PECTORIS; ANOREXIA; ARTICLE; BEAM THERAPY; BREAST ENGORGEMENT; BREAST TENDERNESS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHEST TIGHTNESS; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG INTERMITTENT THERAPY; DYSPNEA; FATIGUE; GYNECOMASTIA; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMATURIA; HOT FLUSH; HUMAN; IMPOTENCE; KAPLAN MEIER METHOD; LEG EDEMA; LETHARGY; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MOOD CHANGE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MUSCLE CRAMP; NIGHT SWEAT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PHYSICAL PERFORMANCE; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PRURITUS; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; SCORING SYSTEM; SCROTAL PAIN; SEXUAL BEHAVIOR; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; THERAPY EFFECT; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 43249131646     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2008.n.008     Document Type: Article

References (29)

1. M Pether SL Goldenberg K Bhagirath Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience Can J Urol 10 2003 1737 1742
2. MH Rashid UB Chaudhary Intermittent androgen deprivation therapy for prostate cancer Oncologist 9 2004 295 301
3. MS Bhandari J Crook M Hussain Should intermittent androgen suppression be used in routine clinical practice? J Clin Oncol 23 2005 8212 8218
4. U Tunn The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight BJU Int 99 suppl 1 2007 19 22
5. N Bruchovsky L Klotz J Crook Locally advanced prostate cancer – biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy Cancer 109 2007 858 867
6. NJ Keating AJ O'Malley MR Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
7. Aihara K, Tanaka G, Suzuki T, et al. A hybrid system approach to hormonal therapy of prostate cancer and its nonlinear dynamics. In: Tacano M, Yamamoto Y, Nakao M. Proceedings of the 19th International Conference on Noise and Fluctuations, ICNF 2007 :479-82.
8. N Bruchovsky L Klotz J Crook Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer – clinical parameters Cancer 107 2006 389 395
9. P Armitage G Berry JN Matthews Statistical methods in medical research 4th edition 2002 Blackwell New York
10. MJ Barry FJ Fowler Jr MP O'Leary The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association J Urol 148 1992 1549 1557
11. JJ Ware CD Sherbourne The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Med Care 30 1992 473 483
12. R McCorkle ME Cooley JA Shea A user's manual for the symptom distress scale 1998 University of Pennsylvania Philadelphia
13. R Development Core Team (2006). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0 Available at: http://www.R-project.org Accessed: April 7, 2008
14. F Harrell Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis 2001 Springer-Verlag New York
15. EL Kaplan P Meier Nonparametric estimation from incomplete observations J Amer Stat Assoc 53 1958 457
16. Table 2a. Complete life table, Canada, 1995-1997: males. Statistics Canada. Canada's national statistical agency [Web site] Available at: http://www.statcan.ca/bsolc/english/bsolc?catno=84-537-XIE1997001&ISSNOT=1 Accessed: August 10, 2004
17. SL Goldenberg N Bruchovsky Use of cyproterone acetate in prostate cancer Urol Clin N Amer 18 1991 111 121
18. M Pavone-Macaluso HJ de Voogt G Viggiano Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group J Urol 136 1986 624 631
19. HJ de Voogt PH Smith M Pavone-Macaluso Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762 J Urol 135 1986 303 307
20. A Falanga L Zacharski Deep vein thrombosis in cancer: the scale of the problem and approaches to management Ann Oncol 16 2005 696 701
21. JL Tenover The androgen-deficient male: current treatment options Rev Urol 5 suppl 1 2003 22 28
22. D Feltquate L Nordquist C Eicher Rapid androgen cycling as treatment for patients with prostate cancer Clin Cancer Res 12 2006 7414 7421
23. TR Pak WC Chung LR Hinds Estrogen receptor-beta mediates dihydrotestosterone-induced stimulation of the arginine vasopressin promoter in neuronal cells Endocrinology 148 2007 3371 3382
24. NA Spry L Kristjanson B Hooton Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer Eur J Cancer 42 2006 1083 1092
25. A De La Taille M Zerbib S Conquy Intermittent androgen suppression in patients with prostate cancer BJU Int 91 2003 18 22
26. A Hurtado-Coll SL Goldenberg ME Gleave Intermittent androgen suppression in prostate cancer: the Canadian experience Urol 60 suppl 3A 2002 52 56
27. S Malone G Perry R Segal Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study BJU Int 96 2005 514 520
28. E Youssef S Tekyi-Mensah K Hart Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer Am J Clin Oncol 26 2003 119 123
29. M Hussain CM Tangen C Higano Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer : data from Southwest Oncology Group Trial 9346(INT-0162) J Clin Oncol 24 2006 3984 3990